

MONEX GROUP

Announcement of Board Member Candidates

TOKYO, February 19, 2024 - Monex Group, Inc. (“the Company”) hereby announces that the Nominating Committee of the Company has decided to propose the appointment of the following candidates to the Board of Directors at the 20th Annual General Meeting of Shareholders scheduled to be held in June 2024.

While the Company feels it is premature to replace current directors who are familiar with our operations, given the significant changes in our operating environment and increasing difficulties in management decision making, we also believe that the appropriate influx of new perspectives to respond to these changes is needed. Considering the skill matrix of current directors, the Company decided that it was necessary to appoint new directors who have technology and financial knowledge, innovation insight, expertise in human capital, diversity, and other aspects of sustainability, and global experience. Furthermore, the Board of Directors and Nominating Committee conducted several comprehensive assessments of the current board structure and confirmed that the current directors have actively attended and participated in board meetings and their respective committee meetings.

As a result, the Company’s Nominating Committee has decided to keep the number of outside directors seven while maintaining the current four inside directors, bringing the total to 11. The Company’s Nominating Committee has resolved to submit a board member candidate election proposal to reappoint eight current directors and appoint three new directors at the 20th Annual General Meeting of Shareholders scheduled to be held in June 2024.

Details about the General Meeting of Shareholders, including the date, time and location, will be disclosed on the Company’s website.

1. The candidates for Members of the Board (11)

Notes:

- Of the eleven candidates, eight are nominated for re-appointment and three are nominated for new appointment. Seven candidates qualify as outside directors.
- < Independent/Outside> indicates an independent and outside director candidate.

Oki Matsumoto *For re-appointment

- Chairman of the Board
- Representative Executive Officer and Chairman

Yuko Seimei *For re-appointment

- Member of the Board
- Representative Executive Officer and Chief Executive Officer

Takashi Oyagi *For re-appointment

- Member of the Board
- Executive Officer and Chief Financial Officer

Naofumi Yamada *For re-appointment

- Member of the Board
- Executive Officer

Jun Makihara <Independent and Outside Director > *For re-appointment

- Member of the Board
- Outside Director, Philip Morris International Inc.

Nobuo Domae <Independent and Outside Director > *For re-appointment

- Member of the Board
- President and Representative Director, Ryohin Keikaku Co., Ltd.

Masaaki Koizumi <Independent and Outside Director > *For re-appointment

- Member of the Board
- Certified Public Accountant (Koizumi C.P.A. Office)

Ungyong Shu <Independent and Outside Director > *For re-appointment

- Member of the Board
- Representative Director, Core Value Management, Co., Ltd.

Sachiko Habu <Independent and Outside Director > (*1) *For new appointment

- Member of the Board
- CEO, HABU Production CO., LTD.

Rami Suzuki <Independent and Outside Director > (*1) *For new appointment

- Member of the Board
- CEO and Representative Director, ARC Therapies Inc.

Ryoko Shimokawa <Independent and Outside Director > (*1) *For new appointment

- Member of the Board
- Group CSuO, Senior Vice President and Executive Officer, SOMPO Holdings, Inc.

*1 The Company will newly submit the appropriate documentation for Ms. Sachiko Habu, Dr. Rami Suzuki, and Ms. Ryoko Shimokawa to be independent directors.

2. Information on board member candidates for new appointment

(career summary, important concurrent positions at other organizations, and reasons for nomination)

Note:

- Important concurrent positions at other organizations are as of February 19, 2024.

Sachiko Habu

(Date of birth: June 16, 1976)

【Career summary】

Apr. 2002	Joined Editorial Engineering Laboratory Co., Ltd.
Apr. 2004	Freelance, Nikkei Home Publications, Inc.
Apr. 2005	Writer, Nikkei Zero One, Nikkei Home Publications, Inc.
Apr. 2006	Writer, Nikkei MONEY, Nikkei Business Publications, Inc.
Apr. 2012	Deputy Editor-in-chief, Nikkei MONEY
Nov. 2013	Founder and Editor-in-chief, Nikkei DUAL
Apr. 2018	Editor-in-chief, Nikkei ecomom
Feb. 2019	Founder and Editor-in-chief, Nikkei xwoman, Nikkei ARIA
Aug. 2019	Editor-in-chief, Nikkei xwoman; Editor, Nikkei doors
Sep. 2021	Editorial committee, Nikkei xwoman
May 2022	Guest Fellow, Nikkei xwoman (present)
Jun. 2022	CEO, HABU Production CO., LTD. (present)
Apr. 2023	Producer, Osaka-Kansai World Expo Women's Pavilion WA (present)
Apr. 2023	Part-time-lecturer, Ochanomizu University (present)

【Important concurrent positions】

- 1) CEO, HABU Production CO., LTD.

【Reasons for nomination as director】

Sachiko Habu has been active in mass media as founder and editor-in-chief of four publications. Guided

by the keyword “diversity,” she promotes diversity management, including women’s empowerment, as a material issue that is directly connected to corporate management strategies. Given her knowledge and experience in mass media, corporate communications, risk management, and human capital focused on diversity, the Group’s Nominating Committee determined that Ms. Habu will provide a new perspective, will further enhance the effectiveness of the Board of Directors, and is a candidate that fulfills the qualities the Company seeks.

Rami Suzuki

(Date of birth: July 15, 1973)

【Career summary】

January 2001	Head, Life Science Venture Capital Fund, ITX Corporation
April 2004	Associate Director, Oncology, Business Development, Eisai Europe
October 2006	Manager, Oncology, Business Development, Eisai Co., Ltd.
October 2014	Unit President, Global Business Development
October 2016	Corporate Officer, Business Development, Eisai Co., Ltd.
April 2017	Head, Medical Affairs Division, Janssen, J&J Family of Companies in Japan
October 2020	CEO and Representative Director, Ferring Pharmaceuticals Co., Ltd.
November 2021	President and Representative Director, Moderna Japan Co., Ltd.
January 2024	CEO and Representative Director, ARC Therapies Inc. (present)
January 2024	Operating Partner, ARCHIMED Group (present)
January 2024	External Board Director, SPERA PHARMA, Inc. (present)
January 2024	External Auditor, Hepalys Pharma, Inc. (present)

【Important concurrent positions】

- 1) CEO and Representative Director, ARC Therapies Inc.
- 2) Operating Partner, ARCHIMED Group
- 3) External Board Director, SPERA PHARMA, Inc.
- 4) External Auditor, Hepalys Pharma, Inc.

【Reasons for nomination as director】

Dr. Rami Suzuki has long worked to resolve important societal issues through medicine. She has a diverse range of global and innovative healthcare-related experience, having been involved in basic research and venture capital at an overseas university, as executive officer in charge of new drug business development at a TSE-listed pharmaceutical company, as top management of a foreign-affiliated healthcare company that provided the COVID-19 vaccine, and now currently, as top management of a healthcare venture business. In discussions at the Group’s Nominating Committee, the Company has determined that the candidate fulfills the qualities sought in terms of global experience, technological knowledge, and management and innovation experience.

Ryoko Shimokawa

(Date of birth: August 15, 1971)

【Career summary】

Apr. 1994	Joined Goldman Sachs Japan Co., Ltd. Worked in the Investment Banking Div. and Merchant Banking Div.
Sep. 2000	Vice President, Buyout Group, The Carlyle Group
July 2007	Joined McDonald’s Company (Japan) as Senior Manager, Business Strategy Dept., Strategic Planning Division
Oct. 2010	Director, Strategy & Planning, Pipeline Mgt. Dept., Restaurant Development Division
Oct. 2015	Senior Director, Brand Extension Dept., National Operations Division
July 2016	Joined SOMPO Himawari Life Insurance Inc. as Senior Deputy GM, Corporate Planning

	Dept.
Apr. 2017	GM, HR/Human Capital Development Dept.
Apr. 2019	Executive Officer, GM of HR/Human Capital Development Dept.
Apr. 2020	Executive Officer and GM of Healthcare Business Development Dept., SOMPO Holdings, Inc.
Aug. 2021	Group Chief Sustainability Officer, Senior Vice President and Executive Officer, SOMPO Holdings, Inc. (present)

【Important concurrent positions】 (* indicates publicly listed company)

- 1) Group Chief Sustainability Officer, Senior Vice President and Executive Officer, SOMPO Holdings, Inc. *

【Reasons for nomination as director】

Ms. Ryoko Shimokawa has global experience and expertise knowledge of financial and capital policies having worked as a financial advisor at a foreign-affiliated securities firm and managed M&As at one of the world's largest investment firms. In addition, she has been involved in human capital-related activities at a listed company and has extensive experience in sustainability, having promoted activities related to human capital as an executive officer. In discussions at the Group's Nominating Committee, the Company has determined that the candidate fulfills the qualities sought in terms of financial, management, global, as well as corporate governance experience, including sustainability, at a listed company.

Contact:	Akiko Kato	Yuki Nakano, Taishi Komori
	Corporate Communications Office	Investor Relations, Financial Control Department
	Monex Group, Inc.	Monex Group, Inc.
	+81-3-4323-3983	+81-3-4323-8698

This material is an English translation of a Japanese announcement made on the date above. Although the Company intended to faithfully translate the Japanese document into English, the accuracy and correctness of this English translation is not guaranteed and thus you are encouraged to refer to the original Japanese document. This translation was made as a matter of record only and does not constitute an offer to sell or to solicit an offer to buy securities in the U.S.